Remote-controlled module-assisted synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine as tumor PET tracer using two different radiochemical routes

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Remote-controlled module-assisted synthesis of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine as tumor PET tracer using two different radiochemical routes

WANG Ming-Wei，

YIN Duan-Zhi，

ZHANG Lan，

ZHOU Wei，

WANG Yong-Xian

Nuclear Science and Techniques

Vol.17, No.3

pp.148-153

Published in print 20 Jun 2006

DOI：10.1016/S1001-8042(06)60029-8

CLC：O621.3

29800

The positron-emitter fluorine-18 labeled amino acid O-(2-[¹⁸F]fluoroethyl)-L-tyrosine ([¹⁸F]FET) has shown very promising perspectives for brain tumor diagnosis with positron emission tomography (PET). There have been two existing preparation routes of [¹⁸F]FET named direct nucleophilic radiofluorination of protected L-tyrosine and radiofluoroalkylation of unprotected L-tyrosine, respectively. A general module was designed specifically for the routine synthesis of [¹⁸F]FET, which could be suitable for the present two chemical methods with simple modifications. The fluorinated intermediates and the final product were separated and purified using solid phase extraction (SPE) on the Sep-Pak silica plus cartridge instead of the time-consuming high performance liquid chromatography (HPLC) procedures. The total synthesis time was about 50—60min with good radiochemical yield (about 20—40%, no-decay-corrected) and good radiochemical purity (more than 97%) for both the synthetic methods.

[18F]FETPETFluorinationFluoroalkylationSynthesis module

References

[1]

Jager P L, Vaalburg W, Pruim J, et al. J Nucl Med, 2001, 42: 432-445.

[2]

Laverman P, Boerman O C, Corstens F H M, et al. Eur J Nucl Med, 2002, 29: 681-690.

[3]

Glaser M, Luthra S K, Brady F. International Journal of Oncology, 2003, 22: 253-267.

[4]

Couturier O, Luxen A, Chatal J F, et al. Eur J Nucl Med Mol Imaging, 2004, 31: 1182-1206.

[5]

Coenen H H, Kling P, Stocklin G. J Nucl Med, 1989, 30: 1367-1372.

[6]

Wienhard K, Herholz K, Coenen H H, et al. J Nucl Med, 1991, 32: 1338-1346.

[7]

Inoue T, Tomiyoshi K, Higuichi T, et al. J Nucl Med, 1998, 39: 663-667.

[8]

Inoue T, Shibasaki T, Oriuchi N, et al. J Nucl Med, 1999, 40: 399-405.

[9]

Heiss P, Mayer S, Herz M, et al. J Nucl Med, 1999, 40: 1367-1373.

[10]

Wester H J, Herz M, Weber W, et al. J Nucl Med, 1999, 40: 205-212.

[11]

Pöpperl G, Götz C, Rachinger W, et al. Eur J Nucl Med Mol Imaging, 2004, 31: 1464-1470.

[12]

Weber W A, Wester H J, Grosu A L, et al. Eur J Nucl Med, 2000, 27: 542-549.

[13]

Weckesser M, Langen K J, Rickert C H, et al. Eur J Nucl Med Mol Imaging, 2005, 32: 422-429.

[14]

Tang G H, Wang M F, Tang XL, et al. Journal of Nuclear and Radiochemistry (in Chinese), 2003, 25: 44-48..

[15]

Hamacher K, Coenen H H. Appl Radiat Isot, 2002, 57: 853-856.

[16]

Wang H E, Wu SY, Chang C W, et al. Nucl Med Biol 2005, 32: 367-375.

[17]

Wang M W, Yin D Z, Wang Y X, et al. Nuclear Science and Techniques, 2005, 16: 283-288.

[18]

Tang G H, Tang X L, Wang M F, et al. J Label Compd Radiopharm 2003, 46: 661-668.

[19]

Wang M W, Yin D Z, Wang Y X, et al. Nuclear Techniques (in Chinese), 2005, 28: 654-658.